Projects

  • EuroNanoMed III – TENTACLES – “TEmperature-responsive Nanogels for TArgeted delivery of miCroRNAs in wound heaLing and tissue rEgeneration applicationS”, 2020-2024 (Šramková)
  • H2020- EU.4.b. Twinning of research institutions, WIDESPREAD-03-2018 Twinning – VISION – “Strategies to strengthen scientific excellence and innoVation capacIty for early diagnoSIs of gastrOintestinal caNcers”, 2019-2023 (Gábelová)
  • SAS-TUBITAK 398784 – “Targeted combination therapy of colon cancer with therapeutic gene/drug loaded novel dendritic nanocarriers”, 2018-2021 (Matúšková)
  • Euronanomed II INNOCENT – “Development of nanomaterial for drug delivery for cancer treatment”, 2017-2020 (Gábelová)
  • H2020- GA685817 – HISENTS “High level Integrated Sensor for Nanotoxicity Screening”, 2016-2019 (Gábelová)
  • SASPRO_0084-01-02 – “Functional consequences of renal cell activation due to iron oxide and gold nanoparticle uptake”, 2015-2018 (Bábelová)
  • APVV-16-0579 – “Gold nanoparticles: impact of physicochemical properties on distribution, accumulation, and biological response in vivo” (BIONANOGOLD), 2017-2021 (Bábelová)
  • APVV-15-0215 – MOR4CML – “Multivalent morpholino-based antisense system for CML”, 2016-2020 (Gábelová)
  • APVV-19-0070 – PRO4CML – “Preclinical validation of an innovative antisense platform for CML”, 2020-2024, (Bábelová)
  • APVV-20-0494 – RENASTHERA – “Novel renal antisense therapy platform for CKD”, 2021-2025 (Bábelová)
  • PP-COVID-20-0007 – ASCOVIDA – “Targeted inhibition of SARS-CoV-2 by a new generation RNA inhibitor”, 2020-2021 (Bábelová)
  • COST CA17140 – NANO2CLINIC – “Cancer Nanomedicine – from the bench to the bedside”, 2018-2023 (Šramková, Kozics)
  • COST CA15132 – hCOMET “The comet assay as a human biomonitoring tool”, 2016-2020 (Gábelová, Šramková)
  • COST CA16119 –  CellFit “In vitro 3-D total cell guidance and fitness”, 2017-2021 (Bábelová, Šramková)
  • 2019/68-CHÚSAV-1 – GlycoPro – “Glycoprofiling of Proteins Present in Serum and Exosomes for Early Prostate Cancer Diagnostics”, 2019-2022 (Gábelová)
  • VEGA 2/0160/21 – “Diagnostic of oncological diseases using aptasensors: development and validation”, 2021-2024 (Bábelová)
  • VEGA 2/0121/21 – “Use of microfluidic systems for risk assessment of xenobiotics”, 2021-2024 (Šramková)
  • VEGA 2/0055/20 – “Newly synthetised thymol derivatives: relationship between structure and biological activity in colorectal in vitro model”, 2020-2023 (Kozics)
  • VEGA 1/0069/20 – “A pilot study of the selective effects of a new generation of RNA interfering agents at the cellular level”, 2020-2023 (Šelc)
  • VEGA 2/0022/18 – “New glucoconjugate-based precursors of pharmaceuticals: structure-activity relationship analysis”, 2018-2021 (Gábelová)
  • VEGA 2/0056/17 – “Induction of apoptosis by betulinic acid coupled to magnetite nanoparticles in human colorectal cell lines”, 2017-2020 (Šramková)
  • VEGA 2/0027/16 – “Antioxidant, anticarcinogenic and photoprotective effects of lavender oil in vitro”, 2016-2019 (Kozics)
  • VEGA 2/0113/15 – “Mechanisms of gold and magnetic nanoparticle effects on renal cells”, 2015-2018 (Bábelová)
  • VEGA 2/0143/13 – “Mechanism of uptake and trafficking of magnetic iron oxide nanoparticles into human tumor and normal (diploid) cells”, 2013-2016 (Gábelová)
  • VEGA 2/0152/13 – “Development of SQUID Gradiometric and Susceptometric Methods for Iron Homeostasis Related Bio-Applications”, 2013-2016 (Gábelová)